Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 460-100-9 | CAS number: -
Sampling time [hours]
Number of micronucleated polychromatic erythrocytes per 2000 [mean±S.D.]
(mean ± S.D.)
Solvent control = physiological saline
TEGO = 1-Ethyl-3 Methyl lmidazolium Ethylsulfate (TEGO IL IMES (PO-2006-63))
Micronucleus test in bone marrow cells of the mouse with 1-Ethyl-3 Methyl Imidazolium Ethylsulfate.
1-Ethyl-3 Methyl Imidazolium Ethylsulfate was tested in the Micronucleus Test in mice, to evaluate its genotoxic effect on erythrocytes in bone marrow. The study procedures described in this report were based on the most recent OECD and EEC guidelines. Batch JA061 07023 of 1-Ethyl-3 Methyl Imidazolium Ethylsulfate was a light yellow liquid with a purity of ± 99.5%. The test substance was dissolved in physiological saline. Five male and five female animals were used in each of the six treatment groups, including negative and positive controls. All groups received a single intraperitoneal injection. The negative and positive control groups were treated with vehicle and 50 mg/kg body weight (b.w.) of cyclophosphamide (CP), respectively. Animals were dosed with 1-Ethyl-3 Methyllmidazolium Ethylsulfate (TEGO IL IMES (PO-2006-63)) at 375 (two groups), 190 (one group), and 95 (one group) mg/kg b.w.. After dosing the animals of the dose level of 375 mg/kg b.w. showed the following toxic signs: quick breathing, convulsions, tremors, eyes closed, ataxia, hunched posture and rough coat. The animals of the dose levels of 190 and 95 mg/kg b.w. showed no abnormalities after dosing except for two male animals of the group treated with 190 mg/kg b.w. which were breathing quickly. Bone marrow of the groups treated with 1-Ethyl-3 Methyl Imidazolium Ethylsulfate (TEGO IL IMES (PO-2006-63)) was sampled 24 or 48 (highest dose only) hours after dosing. Bone marrow of the negative and positive control groups was harvested 24 and 48 hours after dosing, respectively. No increase in the mean frequency of micronucleated polychromatic erythrocytes was observed in the polychromatic erythrocytes of the bone marrow of animals treated with 1-Ethyl-3 Methyl Imidazolium Ethylsulfate. The incidence of micronucleated polychromatic erythrocytes in the bone marrow of all negative control animals was within the historical negative control data range. Cyclophosphamide, the positive control substance, induced a statistically significant increase in the number of micronucleated polychromatic erythrocytes in both sexes. Hence, both criteria for an acceptable assay were met. The groups that were treated with 1-Ethyl-3 Methyl Imidazolium Ethylsulfate showed no decrease in the ratio of polychromatic to normochromatic erythrocytes compared to the negative controls, which reflects a lack of toxic effects of this compound on the erythropoiesis. The groups that were treated with cyclophosphamide showed an expected decrease in the ratio of polychromatic to normochromatic erythrocytes compared to the negative controls, demonstrating toxic effects on erythropoiesis. It is concluded that 1-Ethyl-3 Methyl Imidazolium Ethylsulfate is not clastogenic in the micronucleus test under the experimental conditions described in this report.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Close Do not show this message again